US4505900A
(en)
*
|
1982-05-26 |
1985-03-19 |
Ribi Immunochem Research, Inc. |
Refined detoxified endotoxin product
|
US4866034A
(en)
*
|
1982-05-26 |
1989-09-12 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
CA1225592A
(en)
*
|
1983-08-26 |
1987-08-18 |
Ribi Immunochem Research Inc. |
Refined detoxified endotoxin
|
US4987237A
(en)
*
|
1983-08-26 |
1991-01-22 |
Ribi Immunochem Research, Inc. |
Derivatives of monophosphoryl lipid A
|
US4663306A
(en)
*
|
1983-09-23 |
1987-05-05 |
Ribi Immunochem Research, Inc. |
Pyridine-soluble extract-refined detoxified endotoxin composition and use
|
NL8401226A
(nl)
*
|
1984-04-16 |
1985-11-18 |
Univ Utrecht |
Farmaceutisch produkt met anti-tumorwerking; gebruik van een farmaceutisch produkt of van farmaceutische samenstellingen in een anti-tumortherapie.
|
US4844894A
(en)
*
|
1984-07-12 |
1989-07-04 |
Ribi Immunochem Research Inc. |
Method of inhibiting the onset of septicemia and endotoxemia
|
US4629722A
(en)
*
|
1984-07-12 |
1986-12-16 |
Ribi Immunochem Research, Inc. |
Method of inhibiting the onset of acute radiation syndrome
|
US4806352A
(en)
*
|
1986-04-15 |
1989-02-21 |
Ribi Immunochem Research Inc. |
Immunological lipid emulsion adjuvant
|
US4803070A
(en)
*
|
1986-04-15 |
1989-02-07 |
Ribi Immunochem Research Inc. |
Immunological emulsion adjuvants for polysaccharide vaccines
|
US4877611A
(en)
*
|
1986-04-15 |
1989-10-31 |
Ribi Immunochem Research Inc. |
Vaccine containing tumor antigens and adjuvants
|
US4929604A
(en)
*
|
1986-05-28 |
1990-05-29 |
Board Of Regents, The University Of Texas System |
Lipopolysaccharides of reduced toxicity and the production thereof
|
US4845036A
(en)
*
|
1987-02-03 |
1989-07-04 |
The United States Of America As Represented By The Department Of Health And Human Services |
Process for isolation of the B oligomer of pertussis toxin
|
DE58903323D1
(de)
*
|
1988-06-04 |
1993-03-04 |
Sartorius Gmbh |
Oberschalige elektronische waage.
|
US4950645A
(en)
*
|
1988-07-08 |
1990-08-21 |
Immunotherapeutics, Inc. |
Composition for macrophage activation
|
US5416070A
(en)
*
|
1988-07-08 |
1995-05-16 |
Immunotherapeutics, Inc. |
Composition for macrophage activation
|
US6218166B1
(en)
|
1994-12-09 |
2001-04-17 |
John Wayne Cancer Institute |
Adjuvant incorporation into antigen carrying cells: compositions and methods
|
WO1996020219A2
(en)
*
|
1994-12-28 |
1996-07-04 |
University Of Kentucky |
Murine monoclonal anti-idiotype antibody 3h1
|
US6949244B1
(en)
*
|
1995-12-20 |
2005-09-27 |
The Board Of Trustees Of The University Of Kentucky |
Murine monoclonal anti-idiotype antibody 11D10 and methods of use thereof
|
US20020041872A1
(en)
*
|
1996-04-12 |
2002-04-11 |
Malaya Chatterjee |
Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
|
US6235280B1
(en)
|
1996-04-12 |
2001-05-22 |
Malaya Chatterjee |
Methods of delaying development of CEA-associated tumors using anti-idiotype antibody 3H1
|
US6468782B1
(en)
|
1996-12-05 |
2002-10-22 |
Quadrant Healthcare (Uk) Limited |
Methods of preserving prokaryotic cells and compositions obtained thereby
|
US6491919B2
(en)
*
|
1997-04-01 |
2002-12-10 |
Corixa Corporation |
Aqueous immunologic adjuvant compostions of monophosphoryl lipid A
|
US6274143B1
(en)
|
1997-06-13 |
2001-08-14 |
Malaya Chatterjee |
Methods of delaying development of HMFG-associated tumors using anti-idiotype antibody 11D10
|
US20020098190A1
(en)
*
|
1997-06-13 |
2002-07-25 |
Malaya Chatterjee |
Compositions and methods for treating tumors bearing HMFG and CEA antigens
|
US20020122807A1
(en)
*
|
1998-07-07 |
2002-09-05 |
Dan Michael D. |
Antigen binding fragments, designated 4B5, that specifically detect cancer cells, nucleotides encoding the fragments, and use thereof for the prophylaxis and detection of cancers
|
US6355244B1
(en)
|
1997-11-17 |
2002-03-12 |
University Of Kentucky Research Foundation |
Methods and compositions for the treatment of psoriasis
|
WO2000003724A1
(fr)
*
|
1998-07-16 |
2000-01-27 |
Hayashi, Akira |
Preparations pour immunotherapie anticancereuse comprenant un constituant somatique bacterien en tant qu'ingredient actif
|
US20020068068A1
(en)
*
|
1999-02-02 |
2002-06-06 |
Mahan Michael J. |
Method of creating antibodies and compositions used for same
|
US7026155B2
(en)
|
1999-02-02 |
2006-04-11 |
Regents Of The University Of California |
Method of reducing bacterial proliferation
|
US6566500B1
(en)
*
|
1999-03-30 |
2003-05-20 |
Board Of Regents, The University Of Texas System |
Compositions and methods for modifying toxic effects of proteinaceous compounds
|
US20040002068A1
(en)
|
2000-03-01 |
2004-01-01 |
Corixa Corporation |
Compositions and methods for the detection, diagnosis and therapy of hematological malignancies
|
US20030031684A1
(en)
|
2001-03-30 |
2003-02-13 |
Corixa Corporation |
Methods for the production of 3-O-deactivated-4'-monophosphoryl lipid a (3D-MLA)
|
WO2003073827A2
(en)
*
|
2002-02-28 |
2003-09-12 |
Corixa Corporation |
Methods of modulating dendritic cells using adjuvants
|
US20030224013A1
(en)
*
|
2002-04-19 |
2003-12-04 |
Cole Garry T. |
Methods for protection against Coccidioides spp. infection using Coccidioides spp. urea amidohydrolase (Ure) protein
|
RU2340621C2
(ru)
|
2002-07-08 |
2008-12-10 |
Корикса Корпорейшн |
Способы получения аминоалкилглюкозаминидфосфатов и дисахаридных иммуноэффекторов и их промежуточных соединений
|
ES2358730T3
(es)
|
2002-07-15 |
2011-05-13 |
Board Of Regents, The University Of Texas System |
Anticuerpos seleccionados y péptidos de duramicina que se enlazan a fosfolípidos aniónicos y aminofosfolípidos y sus usos en el tratamiento de infecciones virales y del cáncer.
|
WO2004012751A1
(ja)
*
|
2002-08-02 |
2004-02-12 |
Sumitomo Pharmaceuticals Company, Limited |
細菌細胞壁骨格成分製剤
|
US20040265337A1
(en)
*
|
2002-08-21 |
2004-12-30 |
Zsebo Krisztina M. |
Method of generating an immune response and compositions used for same
|
ES2422171T3
(es)
*
|
2004-02-11 |
2013-09-09 |
Ligocyte Pharmaceuticals Inc |
Antígenos de carbunco y procedimientos de uso
|
WO2005102369A1
(ja)
*
|
2004-04-22 |
2005-11-03 |
Dainippon Sumitomo Pharma Co., Ltd. |
細菌細胞壁骨格成分を含有する製剤
|
US8153116B2
(en)
|
2006-07-11 |
2012-04-10 |
University Of Connecticut |
Use of conditional plasmodium strains lacking an essential gene in malaria vaccination
|
US8128921B2
(en)
*
|
2006-07-11 |
2012-03-06 |
University Of Connecticut |
Use of conditional plasmodium strains lacking nutrient transporters in malaria vaccination
|
JP2013505022A
(ja)
|
2009-09-16 |
2013-02-14 |
バクサート インコーポレーティッド |
H1n1感染を予防するための免疫戦略の方法
|
SG11201508092YA
(en)
|
2013-04-18 |
2015-10-29 |
Immune Design Corp |
Gla monotherapy for use in cancer treatment
|
US9463198B2
(en)
|
2013-06-04 |
2016-10-11 |
Infectious Disease Research Institute |
Compositions and methods for reducing or preventing metastasis
|
WO2015011254A1
(en)
|
2013-07-26 |
2015-01-29 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of bacterial infections
|
CA2922258C
(en)
|
2013-09-19 |
2022-11-29 |
Novavax, Inc. |
Immunogenic middle east respiratory syndrome coronavirus (mers-cov) compositions and methods
|
CA2939581C
(en)
|
2014-02-20 |
2024-01-23 |
Vaxart, Inc. |
Formulations for small intestinal delivery
|
WO2016180852A1
(en)
|
2015-05-12 |
2016-11-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for preparing antigen-specific t cells from an umbilical cord blood sample
|
EP3307239B1
(de)
|
2015-06-12 |
2020-09-16 |
Vaxart, Inc. |
Formulierungen zur freisetzung von rsv- und norovirus-antigenen im dünndarm
|
JP2019511483A
(ja)
|
2016-03-02 |
2019-04-25 |
ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム |
免疫療法のためのsting活性化ナノワクチン
|
US11850279B2
(en)
|
2016-07-13 |
2023-12-26 |
Ohio State Innovation Foundation |
Platforms and methods for optimizing host antigen presentation and host antitumor and antipathogen immunity
|
WO2021178637A1
(en)
|
2020-03-05 |
2021-09-10 |
Iowa State University Research Foundation, Inc. |
IMMUNOGENIC AND VACCINE COMPOSITIONS AGAINST SARS-CoV-2
|